Alexander's, Inc.

Alexander's, Inc.

ALX
Alexander's, Inc.US flagNew York Stock Exchange
275.76
USD
-0.77
- -
1.41BMarket Cap
Alexander's, Inc.
ALX
(New York Stock Exchange)

Recent

price

275.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
34.12
36.28
37.46
38.45
39.29
40.67
44.37
45.07
45.5
44.22
38.89
40.23
40.15
43.86
44.11
41.52
41.22
Revenue per Share
13.01
15.55
132.04
11.14
13.29
15.04
16.91
15.74
6.42
11.74
8.19
25.94
11.24
19.97
8.46
5.5
4.01
Basic EPS, GAAP
6.6
15.29
21.48
14.46
9.68
20.77
25.58
24.13
14.37
24.63
15.24
23.12
20.01
21.27
10.54
14.3
8.81
Free Cash Flow per Basic Share
7.5
12
137.01
11
13
14
16
17
18
18
18
18
18
18
18
18
18
Dividend per Share
60.56
64.11
59.12
59.25
59.52
60.54
61.43
60.15
49.56
43.29
33.46
41.39
34.61
36.56
27
14.48
10.89
Book Value per Share
67.33
71.13
65.03
65.29
68.17
69.02
68.99
67.24
55.72
49.53
39.69
49.3
46.14
46.33
34.46
21.26
17.67
Tangible Book Value per Share
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Basic Weighted Avg Shares
174
185
191
196
201
208
227
231
233
226
199
206
206
225
226
213
212
Sales/Revenue/Turnover
52.23
52.73
49.96
49.64
48.15
45.79
46.47
45.65
43.22
43.95
36.19
36.96
38.61
37.57
36.15
30.58
28.33
Operating Margin (%)
35
37
36
31
32
34
36
39
38
37
35
35
31
34
38
38
38
Depreciation Expense
66
79
674
57
68
77
86
81
33
60
42
133
58
102
43
28
21
Net Income, GAAP
- -
- -
0.13
- -
- -
0.01
0.06
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
38.13
42.87
352.51
28.97
33.82
36.99
38.11
34.92
14.11
26.54
21.06
64.48
28
45.52
19.19
13.24
9.72
Profit Margin (%)
- -
834
571
579
525
535
552
759
454
468
572
580
564
631
471
269
280
Working Capital
1,246
1,081
1,066
1,050
1,028
1,053
1,052
1,240
966
971
1,156
1,090
1,091
1,093
1,103
943
946
LT Debt
344
363
332
334
348
353
353
344
285
254
203
253
236
238
177
109
91
Total Equity
- -
- -
6.72
- -
- -
6.85
7.5
7.05
7.1
8.04
5.58
5.64
5.95
6.36
6.27
5.59
5.21
Return on Invested Capital (%)
- -
- -
51.74
- -
- -
7.51
7.97
7.68
5.59
8.21
5.25
11.61
6.71
12.61
8.43
7.07
6.46
Return on Capital (%)
22.51
24.95
214.31
18.83
22.39
25.06
27.73
25.89
11.7
25.28
21.35
69.35
29.6
56.13
26.65
26.51
22.4
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
987
829
832
LT Finance Leases
114
114
114
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
1,204
1,119
1,213

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
466
305
318
Cash, Cash Equivalents & STI
286
128
76
Accounts Receivable, Net
114
113
111
Inventories
- -
- -
- -
Total Current Liabilities
45
37
38
Payables & Accruals
45
37
38
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.6%
-9.09%
-38.28%
Free Cash Flow
4.05%
6.01%
35.74%
Net Income, GAAP
14.45%
29.08%
-35.03%
Sales/Revenue/Turnover
0.44%
1.49%
-5.83%
Total Cash Common Dividend
2.69%
0.06%
0.05%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
61
53
56
56
226
2025
55
52
53
53
213
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.14
1.63
1.3
- -
8.46
2025
2.4
1.19
1.16
- -
5.5
2026
0.91
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.5
4.5
4.5
- -
18
2025
4.5
4.5
4.5
- -
18
2026
4.5
- -
- -
- -
- -
Business
Alexander's, Inc. (NYSE: ALX) owns, operates and develops retail properties, primarily shopping centers and standalone retail locations anchored by major retailers. The company offers leasing services for retail space; property management and development; and redevelopment of existing assets into mixed-use properties with residential, office and retail components. Its portfolio includes flagship properties such as the Alexander's Building at 731 Lexington Avenue in New York City and Kings Plaza Shopping Center in Brooklyn, New York. Founded in 1955 and headquartered in Paramus, New Jersey, Alexander's primarily serves the New York metropolitan area, with all major properties located in New York State. The company targets national and regional retailers, supermarkets, department stores and entertainment venues as tenants. It operates as a self-administered and self-managed real estate investment trust (REIT) with no subsidiaries or parent company relationships publicly noted. In recent developments, Alexander's continues to focus on strategic property enhancements, including ongoing redevelopment efforts at its 58th Street location in Manhattan to incorporate modern retail and potential residential elements. The company reported stable occupancy rates and rental income growth in its latest quarterly filings amid a resilient retail real estate market. No major acquisitions, partnerships or name changes have been announced in the past 1-2 years.

Company News

APIChatGPT
  • Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

  • ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

  • ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

  • Alexander’s Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased

  • Alexander's Leases 135,000 Square Feet to Target at its Rego Park Shopping Center; Center is 99% Leased

  • Greenridge Exploration Fully Exercises Option for 100% Interest in the Carpenter Lake Uranium Project in Athabasca Basin, Saskatchewan

  • ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

  • Alexander’s Completes Sale of Rego Park I

  • Alexander's Completes Sale of Rego Park I

  • The Most Hated High Yields On Wall Street

  • First Look: Aramco profit jump, Nvidia-Corning deal, GM fined

  • ALX Oncology Q1 Earnings Call Highlights

  • ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

  • ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

  • Alexander's (ALX) Q1 FFO and Revenues Lag Estimates

  • A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34

  • ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

  • Alexander's Declares Quarterly $4.50 Dividend on Common Shares

  • Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

  • ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules